Fierce Biotech August 13, 2024
Only five months after securing a $100 million IPO, Boundless Bio is already laying off some employees as the precision oncology company grapples with low enrollment for a trial of its lead drug.
Boundless describes itself as “the world’s leading ecDNA company” and is focused on extrachromosomal DNA, which are double-stranded molecules that can be the source of cancer-driving genes. The company had been planning to use the nine-figure proceeds from its March IPO to push ahead with its lead CHK1 inhibitor BBI-355, which was already in clinical development for solid tumors, as well as a diagnostic.
But, in a post-market release Aug. 12, CEO Zachary Hornby said the number of patients enrolled in the combination cohorts for the phase...
Today's Sponsors
Today's Sponsor